Skip to main content
. Author manuscript; available in PMC: 2025 Aug 15.
Published in final edited form as: Sci Transl Med. 2024 Nov 20;16(774):eadl2184. doi: 10.1126/scitranslmed.adl2184

Fig. 6. Bone marrow transfer from Sumo1-KO mice confers protection against colitis.

Fig. 6.

(A) DAI, (B) representative colons, (C) group colon lengths and intestinal permeability, and (D) immune cytokines in (A to D), Sumo1-KO, Sumo3-KO, and their wild-type littermate controls at day 7 after 5-day DSS challenge. (E) DAI, (F) body weight, (G) group colon lengths and intestinal permeability, and (H) immune cytokines in (E to H), Sumo1-KO, at day 7 after receiving sham or vagal stimulation (VS) immediately followed by 5-day DSS challenge. (I) DAI, (J) body weight, (K) group colon lengths and intestinal permeability, and (L) immune cytokines in (I to L), Sumo3-KO, at day 7 after receiving sham or vagal stimulation (VS) immediately followed by 5-day DSS challenge. (M) DAI, (N) body weight, (O) group colon lengths and intestinal permeability, and (P) immune cytokines in (M to O), irradiated wild-type DSS (Ir.WT+DSS) mice transferred with wild-type, Sumo1-KO, or Sumo3-KO bone marrow and received 5-day DSS challenge starting at day 28 after bone marrow transplantation and assessed at day 7 after DSS challenge. *P<0.05 vs Control or WT, #P<0.05 vs DSS (n=4, One-way ANOVA with Bonferroni’s post-hoc test). Graphs represent the mean ± SEM of experiments repeated twice on different dates.